Status: Recruiting
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Prospective, open, interventional, randomized, non-commercial trial
Participants needed: 40
Trial details
Phase: Phase 2Age: 5-30Biological sex: AllType: InterventionalSponsor: Anna RaciborskaUpdated: Oct 7, 2026Locations: 1
Eligibility criteria
Age ≥ 5 to ≤ 30 years at the time of qualification. [+11]
Failure to meet any of the inclusion criteria. [+14]